Clinical trials: Small-cell Lung Cancer
Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
Pazopanib in Molecularly Selected Patients With Advanced NSCLC
The purpose of this study is to evaluate how participants with advanced non-small cell lung cancer (NSCLC) that have certain abnormalities in the pazopanib target genes respond to pazopanib treatment.
- Conditions
- Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
- Trial name
- NCT02193152
- Testing
- Pazopanib
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Washington University School of Medicine
Non Small Cell Lung Cancer
Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer
This is a Phase I, open-label, 2-part study in patients with a confirmed diagnosis of epidermal growth factor receptor (EGFR) mutation positive (EGFRm+) non-small cell lung cancer (NSCLC), who have progressed following prior…
- Trial name
- NCT02317016
- Testing
- Pharmacokinetic sampling - AZD9291, AZD9291 tablet dosing, Rosuvastatin
- Where
- 13 sites in United States, France and 2 more
- Volunteers
- 44 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC
The purpose of this study is to find out what effects a new drug, selumetinib, has on lung cancer when receiving standard chemotherapy with pemetrexed and platinum-based chemotherapy.
- Trial name
- NCT02337530
- Testing
- Selumetinib, Pemetrexed, Cisplatin
- Where
- 12 sites in Canada
- Volunteers
- 62 people
- Sponsor
- Canadian Cancer Trials Group
Lung Cancer
Vaccine Therapy in Patients With Stages IIIB/IV Non-Small Cell Lung Cancer Who Have Finished First-Line Chemotherapy
RATIONALE: Vaccines made from gene-modified tumor cells may help the body build an immune response to kill tumor cells. PURPOSE: This randomized phase I/II trial is studying the side effects of vaccine therapy and to see how well…
- Trial name
- NCT00534209
- Testing
- Allogeneic B7.1/HLA-A1
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- University of Miami
Advanced Non-Small Cell Lung Carcinoma
A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer
The primary objective of the study is to compare the objective response rate (ORR) of high dose cemiplimab (HDREGN2810) and standard dose cemiplimab plus ipilimumab combination therapy (SDREGN2810/ipi) to the ORR of standard dose…
- Trial name
- NCT03430063
- Testing
- SDREGN2810, SDREGN2810/ipi, HDREGN2810
- Where
- 31 sites in United States, Belgium and 7 more
- Volunteers
- 28 people
- Sponsor
- Regeneron Pharmaceuticals
Limited Stage Small Cell Lung Cancer, Small Cell Lung Cancer
Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
Despite the fact that the majority of the patients with limited disease SCLC will respond very well to the standard treatment, a great proportion will relapse within 12 - 24 months.
- Trial name
- STIMULI (NCT02046733)
- Testing
- Ipilimumab, Nivolumab
- Where
- 61 sites in Australia, Belgium and 6 more
- Volunteers
- 222 people
- Sponsor
- ETOP IBCSG Partners Foundation
Non Small Cell Lung Cancer
Powered Vascular Stapler in Video-Assisted Thoracoscopic (VAT) Lobectomies
This prospective, randomized, controlled, multi-center study will collect and compare data from the surgeon's current Standard Of Care stapler (for Pulmonary Artery/Pulmonary Vein transection) and powered vascular stapler.
- Trial name
- NCT02702921
- Testing
- Surgeon's 'standard of care' stapler, Ethicon Powered Vascular Stapler
- Where
- United States
- Volunteers
- 201 people
- Sponsor
- Ethicon Endo-Surgery
Non-Small-Cell Lung Cancer
Pioglitazone to Treat Adults Undergoing Surgery for Non-small Cell Lung Cancer
Background: Pioglitazone is a drug that belongs to the class of antidiabetic agents called thiazolidinediones. It is approved for treatment of type 2 diabetes mellitus.
- Trial name
- NCT00923949
- Testing
- Pioglitazone
- Where
- 2 sites in United States
- Volunteers
- 1 people
- Sponsor
- National Cancer Institute (NCI)
Non-Small Cell Lung Cancer
A Study of Tarceva (Erlotinib) in Elderly Patients With Advanced Non-Small Cell Lung Cancer
This study will compare the efficacy and safety of Tarceva (erlotinib) and vinorelbine in chemo-naive elderly patients with advanced non-small cell lung cancer.
- Trial name
- NCT01196078
- Testing
- erlotinib [Tarceva], vinorelbine
- Where
- Taiwan
- Volunteers
- 114 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer, Small Cell Lung Cancer
Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy
This study is a multinational study to compare enzastaurin versus placebo in the treatment of patients with brain metastases of lung cancer.
- Trial name
- NCT00415363
- Testing
- enzastaurin
- Where
- 7 sites in Denmark, Norway and 3 more
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Stage IV or Recurrent Non-Small Cell Lung Cancer
An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer (CheckMate 026)
The purpose of this study is to show that Nivolumab will improve progression free survival in subjects with strongly Stage IV or Recurrent PD-L1+ non-small cell lung cancer when compared to chemotherapy
- Trial name
- NCT02041533
- Testing
- Nivolumab, Gemcitabine, Cisplatin
- Where
- 141 sites in United States, Argentina and 24 more
- Volunteers
- 541 people
- Sponsor
- Bristol-Myers Squibb
Carcinoma, Non-Small-Cell Lung Carcinoma
The Effects of AZD2171 in Patients With Non-Small Cell Lung Cancer or Head & Neck Cancer
This study is to examine the effects on tumors of AZD2171, in the treatment of NSCLC or HNC. The safety and tolerability of AZD2171 will also be studied.
- Conditions
- Carcinoma, Non-Small-Cell Lung Carcinoma, Head and Neck Neoplasms
- Trial name
- NCT00243347
- Testing
- AZD2171
- Where
- 2 sites in United States, Spain
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Non-Small Cell Lung Cancer
Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer
The purpose of this study is to compare the combination of pemetrexed and carboplatin with the combination of docetaxel and carboplatin in terms of survival without Grade 3 or 4 toxicity in previously untreated patients with…
- Trial name
- NCT00520676
- Testing
- pemetrexed, docetaxel, carboplatin
- Where
- 20 sites in Australia, Brazil and 4 more
- Volunteers
- 260 people
- Sponsor
- Eli Lilly and Company
Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive
Phase I, Study in Chinese NSCLC Patients
A Phase I, Open-Label, Two Parts Study to Assess the Safety, Tolerability,Pharmacokinetics and Preliminary Anti-tumour Activity of AZD9291 in Chinese Patients with Advanced Non-Small Cell Lung Cancer who have Progressed Following…
- Trial name
- AURAChinaPK (NCT02529995)
- Testing
- AZD9291 40 mg, AZD9291 80 mg
- Where
- 2 sites in China
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer
Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers
This phase II trial studies how well ponatinib hydrochloride works in treating patients with stage III-IV lung cancer. Ponatinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell…
- Conditions
- Adenocarcinoma of the Lung, Extensive Stage Small Cell Lung Cancer, Limited Stage Small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer
- Trial name
- NCT01935336
- Testing
- Ponatinib
- Where
- United States
- Volunteers
- 171 people
- Sponsor
- University of Colorado, Denver
Nonsmall Cell Lung Cancer, Stage II, Nonsmall Cell Lung Cancer Stage III
Study of Hypofractionated Radiotherapy Alone in Locally Advanced Nonsmall Cell Lung Cancer Patients
The purpose of this research study is to find out what effects (good or bad) may come from a new way of doing radiation therapy for lung cancer.
- Trial name
- NCT04398199
- Testing
- Hypofractionated Radiation Therapy, Radiation Boost
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Wake Forest University Health Sciences
Advanced Stage Non-small Cell Lung Cancer
Evaluate the Mediators of Sensitivity and Resistance to Nivolumab Plus Ipilimumab in Patients With Advanced NSCLCs
The purpose of this study is to closely examine tumor and blood samples from patients treated with nivolumab and ipilimumab in order to try to identify why some patients with lung cancers respond and why some patients do not.
- Trial name
- NCT02350764
- Testing
- nivolumab, pilimumab
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-Small-Cell Lung
Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)
This is a Phase III, randomized, parallel-arm, placebo controlled, double blind, multicenter study assessing the efficacy and safety of durvalumab versus placebo following SoC chemotherapy in patients with completely resected…
- Trial name
- MERMAID-1 (NCT04385368)
- Testing
- Durvalumab + SoC chemotherapy
- Where
- 140 sites in United States, Argentina and 31 more
- Volunteers
- 89 people
- Sponsor
- AstraZeneca
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)
This randomized, multicenter, Phase III, open-label study will evaluate the efficacy and safety of alectinib versus crizotinib and to evaluate the pharmacokinetics of alectinib in asian participants with treatment-naive…
- Trial name
- NCT02838420
- Testing
- Alectinib, Crizotinib
- Where
- 19 sites in China, South Korea and 1 more
- Volunteers
- 187 people
- Sponsor
- Hoffmann-La Roche
Oncology, Melanoma
Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)
This is a Phase 1/2, first-in-human, open-label, dose escalation and dose-expansion study of E-602, administered alone and in combination with cemiplimab.
- Conditions
- Oncology, Melanoma, Ovarian Cancer, NSCLC
- Trial name
- GLIMMER-01 (NCT05259696)
- Testing
- E-602, Cemiplimab
- Where
- 13 sites in United States
- Volunteers
- 69 people
- Sponsor
- Palleon Pharmaceuticals, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.